Cover Image
市場調查報告書

Sunovion Pharmaceuticals Inc.:產品平台分析

Sunovion Pharmaceuticals Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251717
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Sunovion Pharmaceuticals Inc.:產品平台分析 Sunovion Pharmaceuticals Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 55 Pages
簡介

Sunovion Pharmaceuticals Inc. (舊 Sepracor Inc.)是開發中樞神經系統及呼吸疾病治療藥,發展商品化的製藥公司,著重於研究。

本報告提供Sunovion Pharmaceuticals Inc.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Sunovion Pharmaceuticals Inc.的基本資料

  • Sunovion Pharmaceuticals Inc.概要
  • 主要資訊
  • 企業資料

Sunovion Pharmaceuticals Inc.:R&D概要

  • 主要的治療範圍

Sunovion Pharmaceuticals Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Sunovion Pharmaceuticals Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • IND/CTA 被申請了的產品/聯合治療模式
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Sunovion Pharmaceuticals Inc.:藥物簡介

  • eslicarbazepine acetate
  • dasotraline
  • glycopyrrolate
  • DSP-2230
  • DSP-3748
  • SEP-363856
  • SEP-360
  • Small Molecule 1 for Neuropsychiatric Disorders
  • Small Molecule for Neuropsychiatric Disorders
  • Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment
  • EP-103
  • Small Molecules for Central Nervous System Disorders

Sunovion Pharmaceuticals Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sunovion Pharmaceuticals Inc.:最近的開發平台趨勢

Sunovion Pharmaceuticals Inc.:暫停中的計劃

Sunovion Pharmaceuticals Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • dasotraline
    • DSP-1053
    • DSP-8658
    • SEP-228432
    • tecastemizole

Sunovion Pharmaceuticals Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07965CDB

Summary

Global Markets Direct's, 'Sunovion Pharmaceuticals Inc. - Product Pipeline Review - 2016', provides an overview of the Sunovion Pharmaceuticals Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sunovion Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sunovion Pharmaceuticals Inc.
  • The report provides overview of Sunovion Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sunovion Pharmaceuticals Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sunovion Pharmaceuticals Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sunovion Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sunovion Pharmaceuticals Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sunovion Pharmaceuticals Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sunovion Pharmaceuticals Inc. Snapshot
    • Sunovion Pharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Sunovion Pharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sunovion Pharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Sunovion Pharmaceuticals Inc. - Pipeline Products Glance
    • Sunovion Pharmaceuticals Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sunovion Pharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sunovion Pharmaceuticals Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sunovion Pharmaceuticals Inc. - Drug Profiles
    • eslicarbazepine acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dasotraline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glycopyrrolate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-2230
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DSP-3748
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEP-363856
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEP-360
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEP-39
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Neuropsychiatric Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuropsychiatric Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EP-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Modulate GPCR and Ion Channel for Psychiatric Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sunovion Pharmaceuticals Inc. - Pipeline Analysis
    • Sunovion Pharmaceuticals Inc. - Pipeline Products by Target
    • Sunovion Pharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Sunovion Pharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Sunovion Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action
    • Sunovion Pharmaceuticals Inc. - Recent Pipeline Updates
  • Sunovion Pharmaceuticals Inc. - Dormant Projects
  • Sunovion Pharmaceuticals Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • dasotraline
      • DSP-1053
      • DSP-8658
      • SEP-228432
      • tecastemizole
  • Sunovion Pharmaceuticals Inc. - Locations and Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sunovion Pharmaceuticals Inc., Key Information
  • Sunovion Pharmaceuticals Inc., Key Facts
  • Sunovion Pharmaceuticals Inc. - Pipeline by Indication, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016
  • Sunovion Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016
  • Sunovion Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016
  • Sunovion Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Sunovion Pharmaceuticals Inc. - Pre-Registration, 2016
  • Sunovion Pharmaceuticals Inc. - Phase III, 2016
  • Sunovion Pharmaceuticals Inc. - Phase II, 2016
  • Sunovion Pharmaceuticals Inc. - Phase I, 2016
  • Sunovion Pharmaceuticals Inc. - IND/CTA Filed, 2016
  • Sunovion Pharmaceuticals Inc. - Preclinical, 2016
  • Sunovion Pharmaceuticals Inc. - Discovery, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Target, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2016
  • Sunovion Pharmaceuticals Inc. - Recent Pipeline Updates, 2016
  • Sunovion Pharmaceuticals Inc. - Dormant Developmental Projects,2016
  • Sunovion Pharmaceuticals Inc. - Discontinued Pipeline Products, 2016
  • Sunovion Pharmaceuticals Inc., Other Locations
  • Sunovion Pharmaceuticals Inc., Subsidiaries

List of Figures

  • Sunovion Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016
  • Sunovion Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016
  • Sunovion Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016
  • Sunovion Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top